Last 42 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -26.13 | — | — | — | — | 104.58 | — | — | — | — | — | — | — | — | — | 0.42 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 19.59 | — | 194.18 | 197.18 | 11.72 | 4.98 | 8.26 | 8.95 | 14.93 | 8.45 | 19.99 | 10.87 | 6.78 | 20.76 | 4.24 | 0.32 | 38.85 | 16.16 | 52.46 | 10.77 | 86.29 |
| — | — | +2250.3% | +2103.2% | -21.5% | -41.0% | -58.7% | -17.7% | +120.4% | -59.3% | +371.6% | +3244.7% | -82.6% | +28.5% | -91.9% | -97.0% | -55.0% | -93.6% | -91.7% | -72.0% | -61.5% | |
| P/B Ratio | 7.92 | 0.02 | 11.43 | 7.39 | 4.04 | 2.90 | 2.76 | 3.28 | 2.60 | 1.60 | 1.83 | 1.58 | 1.05 | 1.29 | 1.27 | 1.06 | 2.27 | 1.58 | 1.42 | 3.44 | 5.44 |
| — | -99.2% | +314.7% | +125.3% | +55.3% | +81.4% | +50.5% | +107.1% | +147.0% | +23.6% | +43.7% | +49.2% | -53.6% | -18.2% | -10.5% | -69.1% | -58.2% | -71.5% | -66.9% | -41.7% | -0.8% | |
| P/FCF | — | — | — | — | — | 21.70 | — | — | — | — | — | 15.08 | — | — | — | 0.41 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | +3566.8% | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | 87.75 | — | — | — | — | — | — | — | — | — | 0.12 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.12 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | -18.2% | 32.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -462.8% | -27.6% | 86.9% | -1310.0% | -929.4% | -3162.5% | -175.2% | -1035.2% |
| — | — | -118.2% | -67.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +121.6% | +461.7% | +15.1% | +107.6% | +50.2% | +99.1% | +149.6% | -26.5% | +66.4% | +53.3% | -14.0% | +47.1% | |
| Operating Margin | -87.3% | — | -1956.7% | -1755.5% | -80.1% | -1.4% | -94.5% | -71.6% | -213.8% | -222.9% | -376.9% | -138.4% | -201.4% | -772.8% | -76.7% | 79.4% | -1914.0% | -1209.5% | -3793.6% | -205.6% | -1387.1% |
| — | — | -1971.1% | -2352.0% | +62.5% | +99.4% | +74.9% | +48.3% | -6.2% | +71.2% | -391.5% | -274.4% | +89.5% | +36.1% | +98.0% | +138.6% | -38.0% | +68.9% | +45.6% | +14.1% | +50.3% | |
| Net Margin | -76.6% | — | -1834.0% | -1638.5% | -71.0% | 4.8% | -83.5% | -75.8% | -186.6% | -195.8% | -315.6% | -85.6% | -173.8% | -730.5% | -68.4% | 76.9% | -1818.5% | -1187.4% | -3790.4% | -197.0% | -1378.4% |
| — | — | -2096.5% | -2063.1% | +62.0% | +102.4% | +73.5% | +11.5% | -7.3% | +73.2% | -361.0% | -211.3% | +90.4% | +38.5% | +98.2% | +139.0% | -31.9% | +68.9% | +45.3% | +18.5% | +49.8% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -26.7% | -111.8% | -20.4% | -14.0% | -6.0% | 0.7% | -6.8% | -6.7% | -7.7% | -8.9% | -7.0% | -3.3% | -6.6% | -11.1% | -5.0% | 92.0% | -23.8% | -25.6% | -27.3% | -14.8% | -20.2% |
| — | -16010.5% | -199.7% | -110.2% | +22.4% | +107.9% | +2.7% | -104.5% | -17.5% | +19.5% | -39.1% | -103.5% | +72.4% | +56.7% | +81.6% | +720.3% | -17.9% | -32.5% | -141.2% | -64.8% | -28.4% | |
| ROA | -20.0% | -22.7% | -10.7% | -11.1% | -4.9% | 0.6% | -5.1% | -4.9% | -6.0% | -7.0% | -5.6% | -2.5% | -5.0% | -8.5% | -3.9% | 65.2% | -14.3% | -16.2% | -17.7% | -9.7% | -13.6% |
| — | -4176.7% | -110.2% | -124.0% | +18.3% | +107.9% | +8.7% | -94.3% | -20.2% | +17.1% | -43.1% | -103.9% | +65.4% | +47.4% | +78.0% | +774.2% | -5.3% | -15.2% | -104.5% | -41.7% | -10.3% | |
| ROIC | -25.9% | — | -38.8% | -12.7% | -6.3% | -0.2% | -6.9% | -6.0% | -8.3% | -9.1% | -8.3% | -5.1% | -7.2% | -12.4% | -9.3% | 204.8% | -44.6% | -104.6% | -92.1% | -45.3% | -60.2% |
| — | — | -464.5% | -112.6% | +24.2% | +97.9% | +17.2% | -17.8% | -14.6% | +26.4% | +10.8% | -102.5% | +83.8% | +88.1% | +89.9% | +552.0% | +26.0% | -104.2% | -285.7% | -199.9% | -159.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.20 | 0.10 | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 | 0.06 | 0.05 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.17 | 0.14 | 0.11 | 0.13 | 0.11 |
| — | +256.7% | +83.4% | +24.5% | +7.0% | +13.0% | -1.4% | -5.0% | -11.2% | -18.6% | -0.3% | +0.8% | -62.9% | -57.8% | -48.8% | -56.1% | +54.7% | +45.4% | +404.9% | +515.6% | +486.3% | |
| Debt / EBITDA | — | — | — | — | — | 7.35 | — | — | — | — | — | — | — | — | — | 0.09 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.52 | 6.32 | 10.82 | 5.52 | 6.94 | 7.69 | 4.71 | 3.40 | 4.10 | 7.01 | 6.92 | 7.41 | 5.14 | 4.49 | 6.33 | 5.70 | 3.30 | 3.28 | 4.05 | 4.01 | 4.46 |
| — | -17.9% | +129.8% | +62.1% | +69.4% | +9.7% | -32.0% | -54.0% | -20.3% | +56.0% | +9.3% | +30.0% | +55.7% | +36.8% | +56.3% | +42.0% | -26.0% | -30.6% | -34.2% | -24.5% | -11.2% | |
| Quick Ratio | 5.52 | 6.32 | 10.82 | 5.52 | 6.94 | 7.69 | 4.71 | 3.40 | 4.10 | 7.01 | 6.92 | 7.41 | 5.14 | 4.49 | 6.33 | 5.70 | 3.30 | 3.28 | 4.05 | 4.01 | 4.46 |
| — | -17.9% | +129.8% | +62.1% | +69.4% | +9.7% | -32.0% | -54.0% | -20.3% | +56.0% | +9.3% | +30.0% | +55.7% | +36.8% | +56.3% | +42.0% | -26.0% | -30.6% | -34.2% | -24.5% | -11.2% | |
| Interest Coverage | — | -6.40 | -21.44 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 42 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ZYME stock.
Zymeworks Inc.'s current P/E is -26.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Zymeworks Inc.'s current operating margin is -87.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Zymeworks Inc.'s business trajectory between earnings reports.